First experience with 224Radium-labeled microparticles (Radspherin®) after CRS-HIPEC for peritoneal metastasis in colorectal cancer (a phase 1 study)

First experience with 224Radium-labeled microparticles (Radspherin®) after CRS-HIPEC for peritoneal metastasis in colorectal cancer (a phase 1 study)

BackgroundPeritoneal metastasis (PM) from colorectal cancer carries a dismal prognosis despite extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). With a median time to recurrence of 11–12 months, there is a need for novel therapies. Radspherin® consists of the...

Full description

Bibliographic Details
Main Authors: Stein Gunnar Larsen, Wilhelm Graf, Anthony Burton Mariathasan, Olaf Sørensen, Milan Spasojevic, Mariusz Adam Goscinski, Silje Selboe, Nadja Lundstrøm, Anne Holtermann, Mona-Elisabeth Revheim, Øyvind Sverre Bruland
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Medicine
Subjects:
metastatic colorectal cancer
peritoneal metastasis
cytoreductive surgery
hyperthermic intraperitoneal chemotherapy
224Ra
alpha emitter
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2023.1070362/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2023.1070362/full

Similar Items